ifosfamide has been researched along with Peritoneal Carcinomatosis in 31 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the feasibility and efficacy of doxorubicin dose-escalated chemotherapy in combination with ifosfamide in patients with malignant mesothelioma." | 9.07 | A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. ( Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P, 1994) |
| "Twenty-six patients with unresectable diffuse malignant mesothelioma were enrolled in Southwest Oncology Group (SWOG) study 8731 and treated with ifosfamide, 2 g/m2 intravenously for 4 days, and mesna 2 g/m2 intravenously for 5 days, every 3 weeks." | 9.07 | A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. ( Balcerzak, SP; Berenberg, JL; Keppen, MD; Metch, B; Militello, L; Pierce, HI; Zidar, BL, 1992) |
| "Forty three patients with histologically confirmed malignant mesothelioma were entered onto an Eastern Cooperative Oncology Group phase II study of ifosfamide given with mesna." | 9.07 | An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. ( Borden, EC; Falkson, CI; Falkson, G; Hayes, JA; Hunt, M; Smith, TJ, 1992) |
| "We report a case of retroperitoneal dedifferentiated liposarcoma treated effectively with high-dose ifosfamide." | 7.70 | [A case of advanced retroperitoneal dedifferentiated liposarcoma treated effectively with high-dose ifosfamide]. ( Fujinami, K; Kondoh, I; Kondoh, K; Kushida, K; Miura, T, 1999) |
| "Primary mesenteric liposarcoma is a rare entity that has been reported only 14 times in English literature." | 5.33 | A case of resected huge ileocolonic mesenteric liposarcoma which responded to pre-operative chemotherapy using doxorubicin, cisplatin and ifosfamide. ( Chuman, H; Ishiguro, S; Moriya, Y; Yamamoto, S, 2006) |
| "This study investigated the feasibility and efficacy of doxorubicin dose-escalated chemotherapy in combination with ifosfamide in patients with malignant mesothelioma." | 5.07 | A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. ( Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P, 1994) |
| "Twenty-six patients with unresectable diffuse malignant mesothelioma were enrolled in Southwest Oncology Group (SWOG) study 8731 and treated with ifosfamide, 2 g/m2 intravenously for 4 days, and mesna 2 g/m2 intravenously for 5 days, every 3 weeks." | 5.07 | A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. ( Balcerzak, SP; Berenberg, JL; Keppen, MD; Metch, B; Militello, L; Pierce, HI; Zidar, BL, 1992) |
| "Forty three patients with histologically confirmed malignant mesothelioma were entered onto an Eastern Cooperative Oncology Group phase II study of ifosfamide given with mesna." | 5.07 | An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. ( Borden, EC; Falkson, CI; Falkson, G; Hayes, JA; Hunt, M; Smith, TJ, 1992) |
| "We present a patient with peritoneal carcinosarcoma who was treated with the alkylating agent ifosfamide and experienced a rapid decline in mental status." | 4.90 | Ifosfamide chemotherapy and nonconvulsive status epilepticus: case report and review of the literature. ( Friedman, D; Racela, R; Taupin, D, 2014) |
| "We report a case of postoperative recurrence of liposarcoma of the mesenterium successfully treated by chemotherapy using ifosfamide (IFM) and cisplatin (CDDP)." | 3.73 | [A case of liposarcoma of the sigmoid colon mesenterium successfully treated with chemotherapy]. ( Aoki, T; Kondo, M; Mizumura, Y; Moritani, M; Sasaki, Y; Tsuchida, A; Wada, T; Yamamoto, K, 2006) |
| "We report a case of retroperitoneal dedifferentiated liposarcoma treated effectively with high-dose ifosfamide." | 3.70 | [A case of advanced retroperitoneal dedifferentiated liposarcoma treated effectively with high-dose ifosfamide]. ( Fujinami, K; Kondoh, I; Kondoh, K; Kushida, K; Miura, T, 1999) |
| "Ifosfamide has been shown to possess modest activity in patients with platinum/cyclophosphamide refractory ovarian cancer." | 2.69 | Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. ( Belinson, J; Hurteau, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Sutton, G; Webster, K, 1998) |
| "Intraperitoneal carcinomatosis (PC) may occur with several tumor entities." | 2.49 | Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy. ( Binder, S; Keese, M; Lewis, AL; Löhr, JM, 2013) |
| "treatment with ifosfamide alone or ifosfamide combined with microencapsulated CYP2B1 expressing cells." | 1.34 | Targeted intraabdominal chemotherapy for peritoneal carcinomatosis. ( Löhr, M; Samel, S, 2007) |
| "treatment with ifosfamide alone or ifosfamide combined with microencapsulated CYP2B1-expressing cells." | 1.33 | Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide. ( Hafner, M; Jesnowski, R; Keese, M; Löhr, M; Lux, A; Post, S; Prosst, R; Saller, R; Samel, S; Sturm, J, 2006) |
| "Angiosarcomas are rare soft tissue malignancies." | 1.33 | Metastatic angiosarcoma of the kidney: a case report with treatment approach and review of the literature. ( Bearz, A; Berretta, M; Berretta, S; Brollo, A; Buonadonna, A; Canzonieri, V; Frustaci, S; Morra, A; Rupolo, M; Tirelli, U, 2006) |
| "Primary mesenteric liposarcoma is a rare entity that has been reported only 14 times in English literature." | 1.33 | A case of resected huge ileocolonic mesenteric liposarcoma which responded to pre-operative chemotherapy using doxorubicin, cisplatin and ifosfamide. ( Chuman, H; Ishiguro, S; Moriya, Y; Yamamoto, S, 2006) |
| " As cytostatics for hyperthermic peritoneal perfusion, we have used Mitomycin in a dosage of 18 mg/m2 plus Melphalan in a dosage of 25 mg/m2." | 1.32 | Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases. ( Müller, H; Nakchbandi, V, 2004) |
| "The authors report a case of encephalopathy after treatment with ifosfamide treated by a methylene blue infusion." | 1.29 | [Treatment of ifosfamide induced encephalopathy with methylene-blue]. ( Dreyfus, G; Eftekari, P; Ferrero, JM; Largillier, R; Namer, M, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.45) | 18.7374 |
| 1990's | 10 (32.26) | 18.2507 |
| 2000's | 11 (35.48) | 29.6817 |
| 2010's | 7 (22.58) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Sjoberg Bexelius, T | 1 |
| Chisholm, JC | 1 |
| Okoye, B | 1 |
| Cecil, T | 1 |
| Angelini, P | 1 |
| Dayal, S | 1 |
| Taupin, D | 1 |
| Racela, R | 1 |
| Friedman, D | 1 |
| Binder, S | 1 |
| Lewis, AL | 1 |
| Löhr, JM | 1 |
| Keese, M | 2 |
| Lee, M | 1 |
| Kim, SW | 1 |
| Nam, EJ | 1 |
| Cho, H | 1 |
| Kim, JH | 1 |
| Kim, YT | 1 |
| Kim, S | 1 |
| Fizazi, K | 1 |
| Pagliaro, L | 1 |
| Laplanche, A | 1 |
| Fléchon, A | 1 |
| Mardiak, J | 1 |
| Geoffrois, L | 1 |
| Kerbrat, P | 1 |
| Chevreau, C | 1 |
| Delva, R | 1 |
| Rolland, F | 1 |
| Theodore, C | 1 |
| Roubaud, G | 1 |
| Gravis, G | 1 |
| Eymard, JC | 1 |
| Malhaire, JP | 1 |
| Linassier, C | 1 |
| Habibian, M | 1 |
| Martin, AL | 1 |
| Journeau, F | 1 |
| Reckova, M | 1 |
| Logothetis, C | 1 |
| Culine, S | 1 |
| Jaśkowski, P | 1 |
| Krzanowska, K | 1 |
| Miarka, P | 1 |
| Krzanowski, M | 1 |
| Sułowicz, W | 1 |
| Honoré, C | 1 |
| Atallah, V | 1 |
| Mir, O | 1 |
| Orbach, D | 1 |
| Ferron, G | 1 |
| LePéchoux, C | 1 |
| Delhorme, JB | 1 |
| Philippe-Chomette, P | 1 |
| Sarnacki, S | 1 |
| Msika, S | 1 |
| Terrier, P | 1 |
| Glehen, O | 1 |
| Martelli, H | 1 |
| Minard-Colin, V | 1 |
| Bertucci, F | 1 |
| Blay, JY | 1 |
| Bonvalot, S | 1 |
| Elias, D | 1 |
| LeCesne, A | 1 |
| Sargos, P | 1 |
| Sneag, DB | 1 |
| Ramaiya, N | 1 |
| O'Regan, KN | 1 |
| Jagannathan, JP | 1 |
| Hornick, JL | 1 |
| Ho, VT | 1 |
| Hayes, JH | 1 |
| Boisselier, P | 1 |
| Foucher, F | 1 |
| Boucher, E | 1 |
| Raoul, JL | 1 |
| Suhr, M | 1 |
| Gottschalk, J | 1 |
| Kreusch, T | 1 |
| Müller, H | 1 |
| Nakchbandi, V | 1 |
| Hemmings, C | 1 |
| Fisher, C | 1 |
| de Bree, E | 1 |
| Romanos, J | 1 |
| Relakis, K | 1 |
| Tsiftsis, DD | 1 |
| Dusenbery, KE | 1 |
| Potish, RA | 1 |
| Argenta, PA | 1 |
| Judson, PL | 1 |
| Samel, S | 2 |
| Lux, A | 1 |
| Jesnowski, R | 1 |
| Prosst, R | 1 |
| Saller, R | 1 |
| Hafner, M | 1 |
| Sturm, J | 1 |
| Post, S | 1 |
| Löhr, M | 2 |
| Sasaki, Y | 1 |
| Moritani, M | 1 |
| Wada, T | 1 |
| Mizumura, Y | 1 |
| Kondo, M | 1 |
| Yamamoto, K | 1 |
| Tsuchida, A | 1 |
| Aoki, T | 1 |
| Berretta, M | 1 |
| Rupolo, M | 1 |
| Buonadonna, A | 1 |
| Canzonieri, V | 1 |
| Brollo, A | 1 |
| Morra, A | 1 |
| Berretta, S | 1 |
| Bearz, A | 1 |
| Tirelli, U | 1 |
| Frustaci, S | 1 |
| Ishiguro, S | 1 |
| Yamamoto, S | 1 |
| Chuman, H | 1 |
| Moriya, Y | 1 |
| Miyahara, K | 1 |
| Ferrero, JM | 1 |
| Eftekari, P | 1 |
| Largillier, R | 1 |
| Dreyfus, G | 1 |
| Namer, M | 1 |
| de Jonge, MJ | 1 |
| van Dam, PA | 1 |
| Van Marck, E | 2 |
| Prove, A | 2 |
| van Oosterom, AT | 2 |
| Dirix, LY | 1 |
| van Meerbeeck, J | 1 |
| Schrijvers, D | 1 |
| Corthouts, B | 1 |
| Vermeire, P | 1 |
| Raspagliesi, F | 1 |
| Quattrone, P | 1 |
| Grosso, G | 1 |
| Cobellis, L | 1 |
| Di Re, E | 1 |
| Markman, M | 1 |
| Kennedy, A | 1 |
| Sutton, G | 1 |
| Hurteau, J | 1 |
| Webster, K | 1 |
| Peterson, G | 1 |
| Kulp, B | 1 |
| Belinson, J | 1 |
| Fujinami, K | 1 |
| Kondoh, K | 1 |
| Kondoh, I | 1 |
| Miura, T | 1 |
| Kushida, K | 1 |
| Zidar, BL | 1 |
| Metch, B | 1 |
| Balcerzak, SP | 1 |
| Pierce, HI | 1 |
| Militello, L | 1 |
| Keppen, MD | 1 |
| Berenberg, JL | 1 |
| Falkson, G | 1 |
| Hunt, M | 1 |
| Borden, EC | 1 |
| Hayes, JA | 1 |
| Falkson, CI | 1 |
| Smith, TJ | 1 |
| Chauffert, B | 1 |
| Dimanche-Boitrel, MT | 1 |
| Genne, P | 1 |
| Petit, JM | 1 |
| Onier, N | 1 |
| Jeannin, JF | 1 |
| Pratt, CB | 1 |
| Meyer, WH | 1 |
| Jenkins, JJ | 1 |
| Avery, L | 1 |
| McKay, CP | 1 |
| Wyatt, RJ | 1 |
| Hancock, ML | 1 |
| Nishida, T | 1 |
| Obuchi, T | 1 |
| Sasaki, T | 1 |
| Nagasue, N | 1 |
| Yakushiji, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intra-tumor Injection of Drug-eluting Microspheres Loading With Chemodrug Plus Checkpoint Inhibitors and IL2 for Treatment of Advanced Solid Tumors[NCT04770207] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-11-01 | Recruiting | ||
| A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors[NCT00104676] | Phase 3 | 263 participants (Actual) | Interventional | 2003-11-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluated the overall survival in both groups in participants presenting fast and slow decrease in serum levels of tumor markers. The median overall survival was defined as the median percentage of participants alive after 1 course of treatment. (NCT00104676)
Timeframe: 3 years from randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 65 |
| Arm II | 73 |
Primary objective is to compare the progression-free survival of participants after 1 cycle of treatment, treated randomly by 3 additional cycles of BEP (Arm I) or by T-BEP-Oxaliplatin/cisplatin-ifosfamide-Bleomycin (Arm II). The median progression-free survival rate was defined as the median percentage of participants alive without disease progression after 1 course of treatment. (NCT00104676)
Timeframe: 3 years from randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 48 |
| Arm II | 59 |
3 reviews available for ifosfamide and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Ifosfamide chemotherapy and nonconvulsive status epilepticus: case report and review of the literature.
Topics: Carcinosarcoma; Cerebral Cortex; Diagnosis, Differential; Electroencephalography; Epilepsy, Generali | 2014 |
Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell- and Tissue-Based Therapy; Chemoembolization, Therap | 2013 |
On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Brachytherapy; Chemotherapy, Adjuvant; Combined Modality | 2005 |
5 trials available for ifosfamide and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2014 |
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasibility Studies; Femal | 1994 |
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carboplatin; Cisplatin; Cysta | 1998 |
A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Male; Mesna | 1992 |
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
Topics: Drug Administration Schedule; Female; Humans; Ifosfamide; Infusions, Intravenous; Kidney Diseases; M | 1992 |
23 other studies available for ifosfamide and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Hyperthermic intraperitoneal chemotherapy (HIPEC) as another treatment modality for desmoplastic round cell tumour patients: first paediatric experience from UK.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Cyclophosph | 2021 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherap | 2014 |
[Patient receiving peritoneal dialysis after treatment of ovarian cancer].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; If | 2014 |
Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2017 |
Peritoneal relapse of testicular seminomatous germ cell tumor treated successfully with salvage chemotherapy and autologous stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Ifosfamide; Male; Middle Aged; Pa | 2011 |
[Medical treatment of a voluminous tumor of the mesenteric root].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fibromatosis, Aggressive; Human | 2003 |
Metastatic malignant solitary fibrous tumour to the infra-temporal fossa.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfam | 2003 |
Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Primary omental synovial sarcoma: a case with cytogenetic confirmation.
Topics: Adult; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; D | 2004 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant mixed mesodermal tumours with peritoneal dissemination.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2005 |
Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide.
Topics: Animals; Cytochrome P-450 CYP2B1; Drug Compounding; Genetic Therapy; Ifosfamide; Male; Mice; Mice, I | 2006 |
[A case of liposarcoma of the sigmoid colon mesenterium successfully treated with chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colon, Sigmoid; Drug Administration Sched | 2006 |
Metastatic angiosarcoma of the kidney: a case report with treatment approach and review of the literature.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fat | 2006 |
A case of resected huge ileocolonic mesenteric liposarcoma which responded to pre-operative chemotherapy using doxorubicin, cisplatin and ifosfamide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration S | 2006 |
Targeted intraabdominal chemotherapy for peritoneal carcinomatosis.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Carcinoma; Cell Line, Tumor; Ce | 2007 |
[Chemotherapy of a human pseudomyxoma peritonei transplanted in the nude mouse].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenoma; Doxoru | 1984 |
[Treatment of ifosfamide induced encephalopathy with methylene-blue].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Female; Humans; Ifosfamide; Methylene Blue; | 1995 |
Primary extrauterine müllerian adenosarcoma of the peritoneum.
Topics: Adenosarcoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Do | 1995 |
Malignant degeneration in leiomyomatosis peritonealis disseminata.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Dacarbazine; | 1996 |
[A case of advanced retroperitoneal dedifferentiated liposarcoma treated effectively with high-dose ifosfamide].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 1999 |
[Experimental chemotherapy of peritoneal carcinomatosis of colonic origin in rats].
Topics: Animals; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Disease Models, Anim | 1992 |
Ifosfamide, Fanconi's syndrome, and rickets.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Chronic Kidney Disease-Mineral an | 1991 |
Extragenital malignant mixed Müllerian tumor: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Humans; I | 1988 |